000141397 001__ 141397
000141397 005__ 20240229105126.0
000141397 0247_ $$2doi$$a10.1016/j.ijrobp.2018.07.2004
000141397 0247_ $$2pmid$$apmid:30071292
000141397 0247_ $$2ISSN$$a0360-3016
000141397 0247_ $$2ISSN$$a1879-355X
000141397 0247_ $$2altmetric$$aaltmetric:45962914
000141397 037__ $$aDKFZ-2018-01903
000141397 041__ $$aeng
000141397 082__ $$a610
000141397 1001_ $$0P:(DE-HGF)0$$aBerberich, Anne$$b0$$eFirst author
000141397 245__ $$aNonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients.
000141397 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000141397 3367_ $$2DRIVER$$aarticle
000141397 3367_ $$2DataCite$$aOutput Types/Journal article
000141397 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542796688_24033
000141397 3367_ $$2BibTeX$$aARTICLE
000141397 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141397 3367_ $$00$$2EndNote$$aJournal Article
000141397 520__ $$aBecause treatment options at progression are limited for patients with glioma, accuracy in definition of progression is pivotal. Clinically asymptomatic, newly detected, nonmeasurable, speckled contrast-enhancing lesions (SCEs) without immediate relation to prior immune therapy or radiation therapy appear relatively frequently during the course of disease in patients with glioma and challenge the definition of progression based on Response Assessment in Neuro-oncology criteria. Therefore, data characterizing these SCEs are needed for recommendations of subsequent clinical management.Magnetic resonance imaging of 746 patients with glioma included in this study were retrospectively revised for appearance of newly detected SCEs during the course of disease. Associations with molecular and clinical baseline parameters and their prognostic impact were statistically analyzed, and frequency, natural course, and location of SCEs were described.SCEs occurred more frequently in World Health Organization grade 2 and 3 astrocytoma and oligodendroglial tumors and were significantly associated with isocitrate dehydrogenase mutation in World Health Organization grade 3 astrocytoma and glioblastoma. SCEs mostly remained stable or dissolved in follow-up magnetic resonance imaging, even if no new treatment was initiated. SCEs were frequently located within the tumor or tumor-associated fluid-attenuated inversion recovery abnormalities, but distant appearance also occurred. In patients with glioblastoma, SCEs were associated with a favorable prognosis, which was also observed in the subgroup of patients with glioblastoma with isocitrate dehydrogenase wildtype status.The data demonstrate a predominantly benign course of SCEs after their appearance and emphasize cautious definitions of progression and regular clinical and radiographic follow-up rather than premature initiation of new antitumor therapies until progression is confirmed.
000141397 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141397 588__ $$aDataset connected to CrossRef, PubMed,
000141397 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000141397 7001_ $$0P:(DE-HGF)0$$aKickingereder, Philipp$$b2
000141397 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b3$$udkfz
000141397 7001_ $$aDrüschler, Katharina$$b4
000141397 7001_ $$aRiedemann, Lars$$b5
000141397 7001_ $$aArzt, Marlene$$b6
000141397 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b7$$udkfz
000141397 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b8$$udkfz
000141397 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b9$$udkfz
000141397 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b10$$udkfz
000141397 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b11$$udkfz
000141397 7001_ $$aBendszus, Martin$$b12
000141397 7001_ $$aWick, Antje$$b13
000141397 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2018.07.2004$$gVol. 102, no. 5, p. 1472 - 1480$$n5$$p1472 - 1480$$tInternational journal of radiation oncology, biology, physics$$v102$$x0360-3016$$y2018
000141397 909CO $$ooai:inrepo02.dkfz.de:141397$$pVDB
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000141397 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000141397 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141397 9141_ $$y2018
000141397 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141397 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2017
000141397 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141397 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141397 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141397 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141397 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141397 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141397 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141397 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141397 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141397 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141397 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141397 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2017
000141397 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x0
000141397 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000141397 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x2
000141397 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x3
000141397 980__ $$ajournal
000141397 980__ $$aVDB
000141397 980__ $$aI:(DE-He78)G370-20160331
000141397 980__ $$aI:(DE-He78)C060-20160331
000141397 980__ $$aI:(DE-He78)G160-20160331
000141397 980__ $$aI:(DE-He78)G380-20160331
000141397 980__ $$aUNRESTRICTED